Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voyager-V1 with Checkpoint Inhibitors in Solid Tumors
NCT03647163Phase 2Active, not recruiting
- Sponsor
- Vyriad
- Start
- Apr 2019
- Primary completion
- Jul 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of Voyager-V1 in solid tumor, non-small cell lung cancer (NSCLC), neuroendocrine carcinoma (NEC) and 1 more, sponsored by Vyriad. Primary endpoints: Overall Response Rate at 6 months and Treatment Related Adverse Events at 21 days. Started Apr 2019; status: active, not recruiting.
02
Drugs
Voyager-V1
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)neuroendocrine carcinoma (NEC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03647163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03647163.